Evidence map›Paper›PMID 25759474›Full record

ArticleSchizophrenia bulletin2015

Systematic Integration of Brain eQTL and GWAS Identifies ZNF323 as a Novel Schizophrenia Risk Gene and Suggests Recent Positive Selection Based on Compensatory Advantage on Pulmonary Function.

Xiong-Jian Luo, Manuel Mattheisen, Ming Li, Liang Huang, Marcella Rietschel, Anders D Børglum, Thomas D Als, Edwin J van den Oord, Karolina A Aberg, Ole Mors and 12 more

Open access · goldAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. A review of post-GWAS studies in schizophrenia.Translational psychiatry · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. CFrontiers in neurology · 2020
    Review
  20. Integrative analyses of major histocompatibility complex loci in the genome-wide association studies of major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 6 countries.

Xiong-Jian LuoKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China; These authors contributed equally to this work. luoxiongjian@mail.kiz.ac.cn.
Manuel MattheisenDepartment of Biomedicine and Centre for Integrative Sequencing (iSEQ), Aarhus University, 8000 Aarhus C, Denmark; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus and Copenhagen, Denmark; Department of Genomics, Life & Brain Center, and Institute of Human Genetics, University of Bonn, Bonn, Germany; These authors contributed equally to this work.
Ming LiLieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD;
Liang HuangFirst Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China;
Marcella RietschelDepartment of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany;
Anders D BørglumDepartment of Biomedicine and Centre for Integrative Sequencing (iSEQ), Aarhus University, 8000 Aarhus C, Denmark; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus and Copenhagen, Denmark; Research Department, Psychiatric Hospital, Aarhus University Hospital, Aarhus, Denmark;
Thomas D AlsDepartment of Biomedicine and Centre for Integrative Sequencing (iSEQ), Aarhus University, 8000 Aarhus C, Denmark; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus and Copenhagen, Denmark;
Edwin J van den OordCenter for Biomarker Research and Personalized Medicine, Virginia Commonwealth University;
Karolina A AbergCenter for Biomarker Research and Personalized Medicine, Virginia Commonwealth University;
Ole MorsThe Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus and Copenhagen, Denmark; Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark;
Preben Bo MortensenThe Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus and Copenhagen, Denmark; National Centre for Register-based Research, Aarhus University, Aarhus, Denmark;
Zhenwu LuoDepartment of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC;
Franziska DegenhardtDepartment of Genomics, Life & Brain Center, and Institute of Human Genetics, University of Bonn, Bonn, Germany;
Sven CichonDivision of Medical Genetics, Department of Biomedicine, University Basel, Basel, Switzerland; Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany;
Thomas G SchulzeDepartment of Psychiatry and Psychotherapy, University Medical Center Georg-August-Universität, 37075 Goettingen, Germany; Institute of Psychiatric Phenomics and Genomics (IPPG), Ludwig-Maximilians-University Munich;
Markus M NöthenDepartment of Genomics, Life & Brain Center, and Institute of Human Genetics, University of Bonn, Bonn, Germany;
iPSYCH-GEMS SCZ working group
MooDS SCZ Consortium
Bing SuState Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China;
Zhongming ZhaoDepartments of Biomedical Informatics and Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA;
Lin GanDepartments of Biomedical Informatics and Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA;
Yong-Gang YaoKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China; CAS Center for Excellence in Brain Science, Chinese Academy of Sciences, Shanghai, 200031, China.
Kunming Institute of Zoology · CNAarhus University · DKUniversity of Bonn · DEVirginia Commonwealth University · USAarhus University Hospital · DKFirst Affiliated Hospital of Gannan Medical University · CNForschungszentrum Jülich · DEGenomics (United Kingdom) · GBHeidelberg University · DELieber Institute for Brain Development · USMedical University of South Carolina · USVanderbilt University · US

Funding

Mapping the Genetic Architecture of Complex Disease via RNA-seq and GWAS DataR01LM011177 · NLM · VANDERBILT UNIVERSITY · PI WANG, LILY, ZHAO, ZHONGMING · 2012 to 2014
$1.0M
NLM NIH HHS R01 LM011177NLM NIH HHS R01LM011177
6 · The paper itself

Abstract

Genome-wide association studies have identified multiple risk variants and loci that show robust association with schizophrenia. Nevertheless, it remains unclear how these variants confer risk to schizophrenia. In addition, the driving force that maintains the schizophrenia risk variants in human gene pool is poorly understood. To investigate whether expression-associated genetic variants contribute to schizophrenia susceptibility, we systematically integrated brain expression quantitative trait loci and genome-wide association data of schizophrenia using Sherlock, a Bayesian statistical framework. Our analyses identified ZNF323 as a schizophrenia risk gene (P = 2.22×10(-6)). Subsequent analyses confirmed the association of the ZNF323 and its expression-associated single nucleotide polymorphism rs1150711 in independent samples (gene-expression: P = 1.40×10(-6); single-marker meta-analysis in the combined discovery and replication sample comprising 44123 individuals: P = 6.85×10(-10)). We found that the ZNF323 was significantly downregulated in hippocampus and frontal cortex of schizophrenia patients (P = .0038 and P = .0233, respectively). Evidence for pleiotropic effects was detected (association of rs1150711 with lung function and gene expression of ZNF323 in lung: P = 6.62×10(-5) and P = 9.00×10(-5), respectively) with the risk allele (T allele) for schizophrenia acting as protective allele for lung function. Subsequent population genetics analyses suggest that the risk allele (T) of rs1150711 might have undergone recent positive selection in human population. Our findings suggest that the ZNF323 is a schizophrenia susceptibility gene whose expression may influence schizophrenia risk. Our study also illustrates a possible mechanism for maintaining schizophrenia risk variants in the human gene pool.

Indexed as

Genome-Wide Association StudyDNA-Binding ProteinsDown-RegulationFrontal LobeGene ExpressionGenetic PleiotropyGenetic Predisposition to DiseaseHippocampusHumansLungPolymorphism, Single NucleotideQuantitative Trait LociRiskSchizophreniaSelection, GeneticTranscription FactorsDNA-Binding ProteinsTranscription FactorsZSCAN31 protein, humanassociationeQTLhippocampuspositive selectionschizophreniaZNF323

Identifiers

PMID25759474
PMCPMC4601704
OpenAlexW2106147155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.